CHARACTERIZATION OF LYMPHOBLAST PEPTIDE RECEPTORS
淋巴细胞肽受体的表征
基本信息
- 批准号:3182952
- 负责人:
- 金额:$ 16.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-09-30 至 1990-08-31
- 项目状态:已结题
- 来源:
- 关键词:aminoacid transport antineoplastics cell differentiation cell growth regulation chromosome disorders cytogenetics electrofocusing flow cytometry gel electrophoresis gel filtration chromatography glucose transport hematopoietic stem cells immunofluorescence technique immunoprecipitation insulin insulinlike factor lymphoblast neoplasm /cancer therapy neoplastic growth peptide hormone phosphorylation radioimmunoassay radiotracer tissue /cell culture
项目摘要
In the past, we developed an assay which supports the growth of
malignant colonies from children with acute lymphoblastic
leukemia and non-Hodgkin's lymphoma. Our methodology differs
from in vitro culture techniques reported by others in that (albeit
sporadically) long term cell growth and cell line establishment
from passage of a single colony could be accomplished. Cell line
establishment, however, is important because cell lines provide an
unlimited, stable source of cells for in vitro studies. Cell lines
established in our laboratory have been shown to have the same
immunophenotype, biochemical enzyme profile, immunogenotype
and karyotype as the patient's tumor.
We have recently determined that different subtypes of malignant
lymphoblasts possess unique profiles for receptors to peptide
hormones. While each of 9 immature T-lymphoblast cell lines
possess IGF-I receptors and lack insulin receptors, 19 of 20
immature B-lymphoblast cell lines possess insulin receptors and
lack IGF-I receptors. We have shown that T-lymphoblasts
proliferate in response to nanogram concentrations of IGF-I but
not insulin in serum-free media. Moreover, supplemental IGF-I
has proven to be a key growth factor necessary in the
development of a reproducible, standardized method for the
establishment of T-lymphoblast cell lines in vitro. Based on these
data, we hypothesize that peptide hormones such as insulin and
IGF-I may be critical growth factors necessary for the
proliferation of malignant hematopoietic cells and that peptide
receptor function blockage may severely limit cellular
proliferation. The objective of this proposal is to study the
biologic function of specific peptides (I, IGF-I, IGF-II, CH) on
malignant hematopoietic cells which possess (or lack) specific
peptide receptors, and to determine the specificity, kinetics,
structure and function on specific peptide receptors by binding
studies, chemical cross-linking on SDS-PAGE, receptor
phosphorylation and by polyclonal and monoclonal antireceptor
antibodies. These studies will augment our understanding of
peptide/peptide receptor function in malignant cells, will help
establish standard methodologies for cell line establishment, and
may provide the foundation for antipeptide receptor therapy for
hematopoietic malignancies in the future.
在过去,我们开发了一种支持生长的测定方法,
急性淋巴细胞白血病患儿的恶性集落
白血病和非霍奇金淋巴瘤 我们的方法不同
来自其他人报道的体外培养技术(尽管
零星)长期细胞生长和细胞系建立
从一个单一的殖民地的通道可以完成。 细胞系
然而,建立是重要的,因为细胞系提供了
为体外研究提供无限、稳定的细胞来源。 细胞系
在我们实验室建立的实验室已经被证明具有相同的
免疫表型、生化酶谱、免疫基因型
和染色体组型一样
我们最近发现,不同亚型的恶性肿瘤
淋巴母细胞具有独特的肽受体谱
荷尔蒙 9种未成熟T淋巴母细胞系
有IGF-I受体和缺乏胰岛素受体,19 20
未成熟B淋巴母细胞系具有胰岛素受体,
缺乏IGF-I受体。 我们已经证明T淋巴母细胞
对纳克浓度的IGF-I有反应,
而不是无血清培养基中的胰岛素。 此外,补充IGF-I
已被证明是一个关键的增长因素,
开发可重复的标准化方法,
体外T淋巴母细胞系的建立。 基于这些
数据,我们假设肽激素如胰岛素和
IGF-I可能是关键的生长因子,
恶性造血细胞增殖与肽
受体功能阻断可能会严重限制细胞
增殖 这项建议的目的是研究
特异性肽(I,IGF-I,IGF-II,CH)对
具有(或缺乏)特异性的恶性造血细胞
肽受体,并确定特异性,动力学,
结构和功能对特异性肽受体的影响
研究,SDS-PAGE化学交联,受体
磷酸化和通过多克隆和单克隆抗受体
抗体的 这些研究将增加我们对
肽/肽受体功能的恶性细胞,将有助于
建立用于细胞系建立的标准方法,以及
可能为抗肽受体治疗提供基础,
造血系统恶性肿瘤
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHEN D SMITH其他文献
STEPHEN D SMITH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEPHEN D SMITH', 18)}}的其他基金
CORRELATING MULTIPLE LABELING WITH ARRAY TOMOGRAPHY AND ELECTRON TOMOGRAPHY
将多重标记与阵列断层扫描和电子断层扫描相关联
- 批准号:
8169627 - 财政年份:2010
- 资助金额:
$ 16.07万 - 项目类别:
CORRELATING MULTIPLE LABELING WITH ARRAY TOMOGRAPHY AND ELECTRON TOMOGRAPHY
将多重标记与阵列断层扫描和电子断层扫描相关联
- 批准号:
7957638 - 财政年份:2009
- 资助金额:
$ 16.07万 - 项目类别:
CORRELATING MULTIPLE LABELING WITH ARRAY TOMOGRAPHY AND ELECTRON TOMOGRAPHY
将多重标记与阵列断层扫描和电子断层扫描相关联
- 批准号:
7722475 - 财政年份:2008
- 资助金额:
$ 16.07万 - 项目类别:
相似海外基金
The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
- 批准号:
21K17258 - 财政年份:2021
- 资助金额:
$ 16.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
- 批准号:
499958-2016 - 财政年份:2016
- 资助金额:
$ 16.07万 - 项目类别:
Engage Grants Program
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6623455 - 财政年份:2002
- 资助金额:
$ 16.07万 - 项目类别:
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6465958 - 财政年份:2002
- 资助金额:
$ 16.07万 - 项目类别:
Novel Nanoparticle Delivery System for Antineoplastics
新型抗肿瘤纳米颗粒输送系统
- 批准号:
6483914 - 财政年份:2002
- 资助金额:
$ 16.07万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6124630 - 财政年份:1998
- 资助金额:
$ 16.07万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6329037 - 财政年份:1998
- 资助金额:
$ 16.07万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
2747737 - 财政年份:1998
- 资助金额:
$ 16.07万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459680 - 财政年份:1990
- 资助金额:
$ 16.07万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459678 - 财政年份:1990
- 资助金额:
$ 16.07万 - 项目类别: